1. Evereklioglu C. Current concepts in the etiology and treatment of Behcet disease. Surv Ophthalmol 2005;50:297-350.
2. Onder M, Gurer MA. The multiple faces of Behcet's disease and its aetiological factors. J Eur Acad Dermatol Venereol 2001;15:126-36.
3. Ghate JV, Jorizzo JL. Behcet's disease and complex aphthosis. J Am Acad Dermatol 1999;40:1-18.
4.
Yurdaku
l S, Tüzün Y, Mat MC, Özyazgan Y, Yazıcı H. Behçet sendromu. In: Tüzün Y, Kotoğyan A, Aydemir EH, Baransü O, (eds). Dermatoloji. 2. Baskı. İstanbul, Nobel Tıp Kitapevleri, 1994; 393-9.
5.
Arc
a E, Gür AR. Behçet Hastalığı. T Klin J Med Sci
2003;23:261-8.
6.
Doğanavşargi
l E, Keser G. Behçet Hastalığı. T Klin JIntMed Sci 2005;1:80-91.
7.
Boyva
t A. Behçet hastalığının etiyopatogenezi. T Klin JDermatol 2004;1415-21.
8. Yurdakul S, Hamuryudan V, Yazici H. Behcet syndrome. Curr Opin Rheumatol 2004;16:38-42.
9. Gul A, Ozbek U, Ozturk C, Inanc M, Konice M, Ozcelik T. Coagulation factor V gene mutation increases the risk ofvenous thrombosis in Behcet's disease. Br JRheumatol 1996;35:1178-80.
10. Pay
S
. Behçet hastalığı: etiyoloji ve patogenez. T Klin JIntMed Sci 2005;1:10-8.
11. Reynolds N. Vasculitis in Behçet's syndrome: evidence-based review. Curr Opin Rheumatol 2008;20(3):347-
52.
12.
Önde
r M, Gürer MA. Ülkemizde Behçet hastalığı epidemiyolojisi. T Klin J Int Med Sci 2007;3:4-7.
13.
Sayla
n T, Mat C, Fresko I, Melikoglu M. Behcet's
S.D.Ü. Tıp pak. Derg. 2009:16(3)/ 29-34
34
Yıldırım, behçet hastalığı etyopatogenezi
disease inthe Middle East. ClinDermatol 1999;17:209-
23.
14.
Doğanavşargi
l E, Keser G, Behçet hastalığı. In: Gümüşdiş G, Doğanavşargil E, (eds). Klinik Romatoloji, 1. Baskı. İstanbul, Denizmatbaası, 1999;
423-39.
15.
Zoubouli
s CC. EpidemiologyofAdamantiades-Behcet's disease. Ann Med Interne 1999;150:488-98.
16. Marshall SE. Behcet's disease. Best Pract Res Clin Rheumatol 2004;18:291-311.
17.
Pamu
k ÖN, Çakır N. Behçet hastalığı epidemiyolojisi. T Klin J Int Med Sci 2005;1:3-9.
18.
Zoubouli
s CC, May T. Pathogenesis ofAdamantiades-Behcet's disease. Adv Exp Med Biol 2003;528:161-
71.
19. Gul A, Inanc M, Ocal L, Aral O, Konice M. Familial aggregation ofBehcet's disease in Turkey. Ann Rheum Dis 2000;59:622-5.
20. Lehner T. Immunopathogenesis of Behcet's disease. AnnMedInterne 1999;150:483-7.
21. Durrani K, Papaliodis GN. The genetics of Adamantiades-Behcet's disease. Semin Ophthalmol. 2008;23(1):73-9.
22. Verity DH, Wallace GR, Vaughan RW, Stanford MR. Behcet's disease: from Hippocrates to the third millennium. Br J Ophthalmol 2003;87:1175-83.
23. Krause I, Weinberger A. Behçet's disease. Curr Opin Rheumatol. 2008;20(1):82-7
24. Direskeneli H. Behcet's disease: infectious aetiology, new autoantigens, and HLA-B51. Ann Rheum Dis 2001;60:996-1002.
25. Zierhut M, Mizuki N, Ohno S, Inoko H, Gul A, Onoe K, Isogai E. Immunology and functional genomics of Behçet's disease. Cell Mol Life Sci 2003;60:1903-22.
26. Hamzaoui K, Hamzaoui A, Guemira F, Bessioud M, Hazma M, Ayed K. Cytokine profile in Behçet's disease patients. Scand J Rheumatol 2002;31:205-10.
27. Evereklioglu C, Er H, Turkoz Y, Cekmen M. Serum levels of TNF-alpha, sIL-2R, IL-6, and IL-8 are increased and associated with elevated lipid peroxidation in patients with Behcet's disease. Mediators Inflamm2002;11:87-93.
28. Ilhan F, Demir T, Türkçüoğlu P, Turgut B, Demir N, Gödekmerdan A. Th1 polarization ofthe immune response in uveitis in Behçet's disease.Can J Ophthalmol. 2008;43(1):105-8.
29. Duygulu F, Evereklioglu C, Calis M, Borlu M, Cekmen M, Ascioglu O. Synovial nitric oxide concentrations are increased and correlated with serum levels in patients with active Behcet's disease: a pilot study. Clin Rheumatol 2005;24:324-30.
30. Evereklioglu C, Inaloz HS, Kirtak N, Doganay S, Bulbul M, Ozerol E, Er H, Ozbek E. Serum leptin concentration is increased in patients with Behcet's syndrome and is correlated with disease activity. Br J
Dermatol 2002;147:331-6.
31. Evereklioglu C, Turkoz Y, Er H, Inaloz HS, Ozbek E, Cekmen M. Increased nitric oxide production in patients with Behcet's disease: is it a new activity marker? J Am Acad Dermatol 2002;46:50-4.
32. Yildirim M, Baysal V, Inaloz HS, Doguc D. The significance of serum nitric oxide levels in Behcet's disease and recurrent aphthous stomatitis. J Dermatol 2004;31:983-8.
33. Yilmaz G, Sizmaz S, Yilmaz ED, Duman S, Aydin P. Aqueous humor nitric oxide levels in patients with Behcet disease. Retina 2002;22:330-5.
34. Donmez A, Aksu K, Celik HA, Keser G, Cagirgan S, Omay SB, Inal V, Aydin HH, Tombuloglu M, Doganavsargil E. Thrombin activatable fibrinolysis inhibitor in Behcet's disease. Thromb Res 2005;115:287-92.
35. Aksu K, Turgan N, Oksel F, Keser G, Ozmen D, Kitapcioglu G, Gumusdis G, Bayindir O, Doganavsargil E. Hyperhomocysteinaemia in Behcet's disease. Rheumatology 2001;40:687-90.
36. Er H, Evereklioglu C, Cumurcu T, Turkoz Y, Ozerol E, Sahin K, Doganay S. Serum homocysteine level is increased and correlated with endothelin-1 and nitric oxide in Behcet's disease. Br J Ophthalmol 2002; 86:
653-7
Thank you for copying data from http://www.arastirmax.com